A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.
Researchers at Mayo Clinic, the Carl R. Woese Institute for Genomic Biology (IGB) and from the University of Illinois Macro and Nanotechnology Laboratory (MNTL) are collaborating in a new research theme focusing on using micro RNAs and nanotechnology to develop technologies to characterize tumors and monitor how they grow.
At the University of Illinois, an engineer teamed up with a veterinarian to test a bone cancer drug delivery system in animals bigger than the standard animal model, the mouse. They chose dogs – mammals closer in size and biology to humans – with naturally occurring bone cancers, which also are a lot like human bone tumors.
Despite dramatic advances in diagnostics and treatment, cancer still accounts for nearly 1 in 4 U.S. deaths, as well as over half of disease-related pet mortality. Using translational approaches to discover new and effective treatments for both is the goal of new research theme Anticancer Discovery from Pets to People (ACPP) at the Carl R. Woese Institute for Genomic Biology. Led by Professor of Chemistry Paul Hergenrother, ACPP will leverage discoveries proved in companion animals such as cats and dogs with cancer to pioneer new drugs and novel targets to treat human cancers.
Tumors are notoriously difficult to study in their natural habitat – body tissues – but a new synthetic tissue environment may give cancer researchers the next-best look at tumor growth and behavior.
University of Illinois researchers have developed a new technique to create a cell habitat of squishy fluids, called hydrogels, which can realistically and quickly recreate microenvironments found across biology.
A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.
Most types of tumors, including cancer, require a supply of blood to grow larger than a few millimeters. Scientists have made great progress in combating cancer by finding effective ways to stop the formation of new blood vessels, called angiogenesis.
In four recent papers, University of Illinois Assistant Professor of Bioengineering Princess Imoukhuede and co-authors have made significant progress in personalizing angiogenesis inhibition cancer treatments.